Royalty-free stock photograph created by Mina Rad and Unsplash.
Trade with the United States
The Trump Administration is pushing the deadline for international pharmaceutical companies to enter into onshoring agreements to reduce Section 232 tariffs. The measure, based on national security, directly impacts Spanish exporters, who must decide between relocating production to the US or absorbing the tariff costs.
The US Administration, under the presidency of Donald Trump, has set an imminent deadline for pharmaceutical companies to negotiate tariff reductions Section 232The condition is to commit to moving part of their production to US territory (onshoring), a measure that redefines the rules of the game for the global industry.
This protectionist policy, justified by arguments of "national security," seeks to strengthen the pharmaceutical supply chain of Estados Unidos and reduce their dependence on foreign suppliers, a trend accelerated by the lessons of the pandemic. For international companies, time is running out to make a strategic decision.
The pharmaceutical industry's dilemma: tariffs or relocation
La Section 232 The Trade Expansion Act of 1962 grants the executive branch of EEUU the power to impose tariffs if it is determined that imports of a specific product threaten national security. Its application to the pharmaceutical sector is a clear sign of the current Administration's intention to incentivize local production, in a move that combines the onshoring ’s relationship with the friend shoring (prioritize allied countries).
Companies that do not negotiate a relocation or investment agreement in Estados Unidos They will face the full amount of these tariffs, which could significantly undermine their competitiveness in one of the world's largest and most lucrative markets. The pressure is immense, as the window of opportunity to negotiate these tariff exemptions or reductions is about to close.
Implications for Spanish exporting companies
The Spanish pharmaceutical sector is an export powerhouse, with a strong presence in the North American market. This measure poses a direct challenge to its business model. Foreign trade experts consulted by Empresa Exterior They point out that the executives of Spanish pharmaceutical companies face a crossroads with three possible paths, each with significant financial and operational implications.
The decision is not easy.Ignoring the deadline means accepting a loss of margin or an increase in the final price, risking market share against competitors who do adhere to the agreements or against local producers."Answers an international logistics specialist. On the other hand, a project of onshoring «It requires massive investment in infrastructure, talent, and regulatory compliance in EEUUa step that only large corporations can consider in the short term«.
| Strategic Option | Advantages | Disadvantages |
|---|---|---|
| Pay the tariffs | Maintaining the current production model. No high initial investment. | Loss of competitiveness, reduced margins, possible loss of market share. |
| To adopt 'Onshoring' | Reduction or elimination of tariffs. Preferential market access EEUUShorter supply chain. | High capital investment (CAPEX). Regulatory and operational complexity. Long implementation times. |
| Redirect exports | Avoid the complexity of the market EEUU and investment. | Loss of one of the world's largest pharmaceutical markets. Need to develop new markets. |
Key points and frequently asked questions about Section 232 tariffs
What exactly is Section 232 and why does it apply to the pharmaceutical sector?
La Section 232 It is a US legal provision that allows the imposition of tariffs for national security reasons. Its application to the pharmaceutical sector is part of the Administration's strategy. Trump to ensure self-sufficiency in products considered critical, such as medicines and active ingredients, and thus reduce the vulnerability of its supply chain to global crises.
How does this measure affect a Spanish pharmaceutical company that exports to the US?
The measure directly forces the company to make an immediate decision. If it doesn't act before the deadline, its products will become more expensive when they enter the market. Estados Unidoslosing competitiveness. The alternative is to negotiate an agreement of onshoringThis implies an investment and production plan in US territory in order to benefit from a tariff reduction.
What practical steps should a Spanish manager consider in this situation?
A manager must act urgently. The recommended steps are:
- Financial Impact Analysis: Quantify the cost of tariffs on the portfolio of exported products and assess their effect on profitability.
- Specialized Legal Advice: Hire experts in US commercial law to understand the details of potential agreements onshoring and the requirements to apply for them.
- Supply Chain Assessment: Analyze the feasibility and cost of establishing production operations in EEUU, comparing it with the long-term impact of tariffs.
Any questions about this news?
Talk to Coexia, the AI of the foreign trade
